Advertisement

Subsequent infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with prior infection or fecal colonization

  • Anna Lindblom
  • Nahid Karami
  • Tim Magnusson
  • Christina Åhrén
Original Article

Abstract

In clinical practice, there is a growing need to assess the impact of prior colonization or infection with extended-spectrum β-lactamase-producing Enterobacteriaceae (EPE) on new EPE infections. We have investigated the frequency of, and duration to, a subsequent EPE infection in patients with prior fecal carriage or infection with EPE. Culture data for 3272 EPE-positive patients in Western Sweden during 2004–2014 were evaluated. The median follow-up time was 3.7 years. The first recorded EPE-positive fecal screen, or clinical (urine, blood) culture, and subsequent EPE-positive clinical samples were analyzed, focusing on the first and last recurrence of EPE infection. ESBL Escherichia coli dominated (95%). Almost all (94%) patients initially positive in fecal screen (n = 1436) and 72 and 71% of those initially positive in urine (n = 1717) and blood (n = 119) had no further EPE clinical isolates. Subsequent EPE bacteremia was only detected in 0.7, 1.6, and 4.2% of the respective patient group. Recurrent EPE-positive urine cultures occurred in 27% (460/1717), most (75%) within 6 months, and rarely (13%) after 1 year. Repeated EPE-positive clinical samples were significantly (p < 0.01) more common in patients > 65 years and in men with ESBL Klebsiella pneumoniae. In our low-endemic setting, subsequent EPE infections in previously colonized patients were rare. On the other hand, in patients previously EPE-positive in urine or blood, subsequent EPE urinary tract infections were common, especially within 6 months and in patients > 65 years old.

Keywords

Extended-spectrum β-lactamases (ESBL) E. coli K. pneumoniae Fecal screening Urinary tract infection Bacteremia Recurrent infection 

Notes

Acknowledgements

We thank the personnel at the Clinical Microbiology Laboratory at Sahlgrenska University Hospital for performing the bacterial culturing.

Funding information

This work was supported by the Centre for Antibiotic Resistance Research (CARe), University of Gothenburg and by Region Västra Götaland, Sweden (VGFOUREG-660231).

Compliance with ethical standards

This study was conducted in accordance with the Declaration of Helsinki and national and institutional regulations.

Ethical approval

The study was approved by the Regional Ethical Review Board in Gothenburg, Sweden (recordal: 170-17).

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

No informed consent was required.

References

  1. 1.
    Pitout JD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159–166CrossRefPubMedGoogle Scholar
  2. 2.
    Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiol Rev 18:657–686CrossRefGoogle Scholar
  3. 3.
    World Health Organization (2014) Antimicrobial resistance - Global report on surveillance. Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1
  4. 4.
    Schwaber MJ, Carmeli Y (2007) Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60:913–920CrossRefPubMedGoogle Scholar
  5. 5.
    Melzer M, Petersen I (2007) Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Inf Secur 55:254–259Google Scholar
  6. 6.
    Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, De Pascale G, Proli EM, Cauda R, Cicchetti A, Fadda G (2010) Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 54:4085–4091CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Alevizakos M, Karanika S, Detsis M, Mylonakis E (2016) Colonisation with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents 48:647–654CrossRefPubMedGoogle Scholar
  8. 8.
    Trecarichi EM, Cauda R, Tumbarello M (2012) Detecting risk and predicting patient mortality in patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol 7:1173–1189CrossRefPubMedGoogle Scholar
  9. 9.
    Vodovar D, Marcade G, Rousseau H, Raskine L, Vicaut E, Deye N, Baud FJ, Megarbane B (2014) Predictive factors for extended-spectrum beta-lactamase producing Enterobacteriaceae causing infection among intensive care unit patients with prior colonization. Infection 42:743–748CrossRefPubMedGoogle Scholar
  10. 10.
    Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, Noskin GA, Zembower T (2007) Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect 45:846–852CrossRefGoogle Scholar
  11. 11.
    Rottier WC, Bamberg YR, Dorigo-Zetsma JW, van der Linden PD, Ammerlaan HS, Bonten MJ (2015) Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant enterobacteriaceae bacteremia in patients with sepsis. Clin Infect Dis 60:1622–1630CrossRefPubMedGoogle Scholar
  12. 12.
    Turbett SE, Mansour MK (2016) Editorial commentary: fecal ESBL screening: are we ready for this information? Clin Infect Dis 63:319–321CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488–1495CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available from: http://www.eucast.org/clinical_breakpoints/
  15. 15.
    Karami N, Helldal L, Welinder-Olsson C, Ahren C, Moore ER (2013) Sub-typing of extended-spectrum-beta-lactamase-producing isolates from a nosocomial outbreak: application of a 10-loci generic Escherichia coli multi-locus variable number tandem repeat analysis. PLoS One 8:e83030CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Goulenok T, Ferroni A, Bille E, Lecuyer H, Join-Lambert O, Descamps P, Nassif X, Zahar JR (2013) Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect 84:294–299CrossRefPubMedGoogle Scholar
  17. 17.
    Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, Lopez F, Balasso V, Pozo L, Mensa J (2006) Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 58:1082–1085CrossRefPubMedGoogle Scholar
  18. 18.
    Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, Silva-Sanchez J, Barrios-Camacho H, Najera-Leon E, Velazquez-Acosta C, Vilar-Compte D (2016) Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer 24:253–259CrossRefPubMedGoogle Scholar
  19. 19.
    Arnan M, Gudiol C, Calatayud L, Linares J, Dominguez MA, Batlle M, Ribera JM, Carratala J, Gudiol F (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microb Infect Dis 30:355–360CrossRefGoogle Scholar
  20. 20.
    Ny S, Lofmark S, Borjesson S, Englund S, Ringman M, Bergstrom J, Naucler P, Giske CG, Byfors S (2017) Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study. J Antimicrob Chemother 72:582–588CrossRefPubMedGoogle Scholar
  21. 21.
    Skjot-Rasmussen L, Hammerum AM, Jakobsen L, Lester CH, Larsen P, Frimodt-Moller N (2011) Persisting clones of Escherichia coli isolates from recurrent urinary tract infection in men and women. J Med Microbiol 60:550–554CrossRefPubMedGoogle Scholar
  22. 22.
    Ejrnaes K, Sandvang D, Lundgren B, Ferry S, Holm S, Monsen T, Lundholm R, Frimodt-Moller N (2006) Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. J Clin Microbiol 44:1776–1781CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Banerjee R, Johnson JR (2014) A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother 58:4997–5004CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, Marsh JV, Spear S, Sobel JD, Marty MJ, Marrs CF (2000) Risk factors for second urinary tract infection among college women. Am J Epidemiol 151:1194–1205CrossRefPubMedGoogle Scholar
  25. 25.
    Foxman B (1990) Recurring urinary tract infection: incidence and risk factors. Am J Public Health 80:331–333CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ikaheimo R, Siitonen A, Heiskanen T, Karkkainen U, Kuosmanen P, Lipponen P, Makela PH (1996) Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 22:91–99CrossRefPubMedGoogle Scholar
  27. 27.
    Karkkainen UM, Ikaheimo R, Katila ML, Siitonen A (2000) Recurrence of urinary tract infections in adult patients with community-acquired pyelonephritis caused by E. coli: a 1-year follow-up. Scand J Infect Dis 32:495–499CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Anna Lindblom
    • 1
    • 2
  • Nahid Karami
    • 1
    • 2
  • Tim Magnusson
    • 2
  • Christina Åhrén
    • 1
    • 3
  1. 1.Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy and Centre for Antibiotic Resistance Research (CARe)University of GothenburgGothenburgSweden
  2. 2.Department of Clinical MicrobiologySahlgrenska University HospitalGothenburgSweden
  3. 3.Swedish Strategic Program Against Antimicrobial Resistance (Strama), Region Västra GötalandGothenburgSweden

Personalised recommendations